Gedea Biotech

Gedea Biotech develops pHyph, a CE-marked antibiotic-free treatment for bacterial vaginosis that restores the vaginal microbiome and removes unpleasant odors. The company targets the women's health market, providing a clinical alternative to traditional antibiotics to reduce recurrence and combat antibiotic resistance. Its pipeline also includes research into preventing preterm birth and treating vulvovaginal candidiasis.